J Pediatr Intensive Care 2020; 09(02): 106-112
DOI: 10.1055/s-0039-1700953
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Single-Center Use of Prothrombin Complex Concentrate in Pediatric Patients

1   Division of Pediatric Critical Care Medicine, Nationwide Children's Hospital, Columbus, Ohio, United States
,
Courtney Andersen
2   Ohio University Heritage College of Osteopathic Medicine, Dublin, Ohio, United States
,
3   Division of Pediatric Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, United States
4   Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, United States
5   Department of Anesthesiology and Pain Medicine, The Ohio State University College of Medicine, Columbus, Ohio, United States
› Author Affiliations
Further Information

Publication History

13 October 2019

06 December 2019

Publication Date:
10 January 2020 (online)

Abstract

Coagulation disturbances frequently occur in critically ill children. Four-factor prothrombin complex concentrate (4F-PCC) may have a potential role in managing these patients while avoiding concerns associated with fresh frozen plasma. However, data on this product in critically ill children is scarce. We retrospectively identified 24 critically ill pediatric patients who received 4F-PCC. The primary indication was to correct coagulopathy and control bleeding in the trauma or surgical setting. 4F-PCC effectively decreased the international normalized ratio level, a surrogate marker of hemostasis. Further study is warranted to identify efficacy, indications, optimal dosing, and adverse effects in the critically ill pediatric patients.